Skip to main content

Table 1 Demographic and clinical features of patients with macrophage activation syndrome

From: Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

 TocilizumabHistoric cohort
 Full-blownPossibleAllFull-blownPossibleAll
Number2101210818
Sex, no.
 Female178358
 Male1347310
 Age, median (IQR)6 (3–9)8.5 (7–14.75)8.5 (7–12.75)5 (1.75–6.75)8 (3.5–9.5)5.5 (2–8.25)
 Fever (%, n)50 (1/2)50 (5/10)*50 (6/12)**90 (9/10)100 (8/8)*94.4 (17/18)**
 Hepatosplenomegaly (%, n)0 (0/2)30 (3/10)25 (3/12)40 (4/10)37.5 (3/8)38.9 (7/18)
 Lymphadenopathy (%, n)0 (0/2)20 (2/10)16.7 (2/12)30 (3/10)37.5 (3/8)33.3 (6/18)
 CNS (%, n)0 (0/2)0 (0/10)0 (0/12)0 (0/10)0 (0/8)0 (0/18)
  1. CNS Central nervous system, * = p < 0.05; ** = p < 0.01;